JXR (01951) has announced its financial results for the six months ended June 30, 2026, posting a revenue of RMB 1.373 billion, representing a year-on-year increase of 6.57%. The company achieved a profit attributable to shareholders of RMB 107 million, marking a turnaround from a loss in the prior corresponding period, with basic earnings per share of RMB 0.04.

According to the announcement, the overall increase in revenue was driven by several key factors: (i) a rise of approximately RMB 17.2 million in ARS and related service revenue; (ii) a growth of around RMB 50.8 million in management service revenue; (iii) a slight decrease of roughly RMB 0.1 million in obstetrics and related medical service revenue; (iv) an uptick of approximately RMB 14.7 million in women's health services and other revenue; and (v) an increase of about RMB 2.1 million in sales related to medical consumables and equipment.

The revenue growth was primarily attributed to two main drivers. First, benefiting from California's SB 729 bill officially taking effect in 2026, along with successful physician recruitment over the past three years, the U.S. operations achieved record-high oocyte retrieval cycles in the first half of the year, contributing to a year-on-year revenue increase of RMB 87.1 million. Second, the company's strategic focus on building a full-lifecycle women's health and reproductive health management platform boosted women's health service revenue by RMB 14.7 million year-on-year.

In terms of operational highlights, the VIP product at the Chengdu campus has entered a mature operational phase with strengthening service premium capabilities. During the first half of 2026, the Chengdu Bisheng campus achieved a VIP penetration rate of 21.7%, up approximately one percentage point year-on-year, while the average transaction value per customer increased 6% year-on-year to RMB 71,000.

Since the Shenzhen campus commenced full operations in the second quarter of 2026, its high-net-worth business has already shown early success, supported by four decades of medical expertise and upgraded hardware facilities at the new campus. In addition to a substantial 32.5% growth in initial infertility consultations, VIP penetration rate climbed 6.9 percentage points year-on-year to reach 9.2%, while initial consultations from Hong Kong patients surged 62% compared to the same period last year. Looking ahead, the company plans to capitalize on the strategic advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, with a strong focus on expanding its VIP and international business segments, positioning its high-net-worth services for rapid growth in the near future.